Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).
- DOI
- 10.1007/s41669-019-0130-7
- Published
- 2019 Dec
- Container
- PharmacoEconomics - open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s41669-019-0130-7,
title = {Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).},
author = {Garay OU and Nishimwe ML and Bousmah MA and Janah A and Girard PM and Chêne G and Moinot L and Sagaon-Teyssier L and Meynard JL and Spire B and Boyer S},
year = {2019},
journal = {PharmacoEconomics - open},
doi = {10.1007/s41669-019-0130-7},
url = {https://doi.org/10.1007/s41669-019-0130-7}
}RIS
TY - JOUR TI - Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM). AU - Garay OU AU - Nishimwe ML AU - Bousmah MA AU - Janah A AU - Girard PM AU - Chêne G AU - Moinot L AU - Sagaon-Teyssier L AU - Meynard JL AU - Spire B AU - Boyer S PY - 2019 JO - PharmacoEconomics - open DO - 10.1007/s41669-019-0130-7 UR - https://doi.org/10.1007/s41669-019-0130-7 ER -
APA
OU, G., ML, N., MA, B., A, J., PM, G., G, C., L, M., L, S., JL, M., B, S., & S, B. (2019). Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).. PharmacoEconomics - open. https://doi.org/10.1007/s41669-019-0130-7
Source records
- pubmed · retrieved 2026-09-25T06:43:18.052Z